Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.PepGen: Upgrade To 'Buy' On PGN-EDODM1 Splicing Data Comeback And 2027 Milestones
PepGen Announces Pricing of $125 Million Public Offering
PepGen Announces Pricing of $125 Million Public Offering
PepGen: Stock Soars On DM1 Data, But Caution Warranted On Small Sample Sizes
PepGen Inc. (PEPG) Discusses FREEDOM2 Lowest Dose Cohort Safety, Splicing and vHOT Results Transcript
PepGen Announces Proposed $125.0 Million Public Offering of Common Stock
PepGen Stock Doubles in One Session - Here's Why
PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
PepGen Announces Positive Phase 2 FREEDOM2-DM1 10 mg/kg Results Demonstrating Highest Reported Splicing Correction and Improvements Across Multiple Functional Measures
PepGen, Inc. (NASDAQ:PEPG) Stock Now Rated “Moderate Buy” by Wall Street Analysts
PepGen, Inc. $PEPG Shares Bought by Squarepoint Ops LLC
ADAR1 Capital Management LLC Acquires New Shares in PepGen, Inc. $PEPG
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
PepGen (PEPG) Upgraded to Buy: Here's What You Should Know
PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights